间充质干细胞及其衍生物雾化吸入治疗肺部疾病研究进展

Research progress of mesenchymal stem cells and their derivatives nebulization in the treatment of pulmonary diseases

在急性和慢性肺部疾病中,不适当的免疫反应和异常修复过程可导致肺组织的不可逆损伤,进而导致肺功能下降甚至衰竭,从而导致患者死亡。间充质干细胞(MSCs)及其衍生物因其独特的生理功能和特性,在肺部疾病的细胞和无细胞疗法中显示出广阔的应用前景,并正进入临床转化阶段,但其安全性和有效性仍存在争议。MSCs及其衍生物的雾化给药为肺部疾病的治疗提供了新的机遇和挑战。在一些临床前研究和临床试验中,有证据表明雾化MSCs及其衍生物的给药方式是安全且有效的,这种方法可能是治疗各种复杂肺部疾病的最佳解决方案。然而在将该方法应用于临床之前,应进一步研究各种给药策略及其与不同雾化装置的兼容性。本文就MSCs及其衍生物雾化治疗肺部疾病的研究进展进行综述。

In acute or chronic lung diseases,inappropriate immune response and abnormal repair process can lead to irreversible damage to lung tissue,which in turn leads to decreased lung function and even respiratory failure or death.Mesenchymal stem cells(MSCs)and their derivatives have shown wide application prospects in cell therapy and acellular therapy of lung diseases and are entering the clinical transformation stage because of their unique physiological functions and characteristics,but the safety and efficacy of MSCs and their derivatives are still controversial.Nebulization therapy provides new opportunities and challenges for the innovative treatment of MSCs and their derivatives in lung diseases.In a number of preclinical studies and clinical trials,there have been evidence that atomization therapy of MSCs and their derivatives is safe and effective.This method could be an optimal solution for the treatment of various complex lung diseases.However,extensive research should be carried out on various strategies and their compatibility with different nebulizers before this method can be used in clinical setting.In this paper,we review the research progress of MSCs and their derivatives by nebulization in the treatment of pulmonary diseases.